







an Open Access Journal by MDPI

Alzheimer's Disease: An Update on Novel Therapeutics

Guest Editors:

Dr. Maria Carmo Pereira

Dr. Joana A. Loureiro

Dr. Maria João Ramalho

Dr. Stephanie Andrade

Deadline for manuscript submissions:

closed (20 June 2023)

Message from the Guest Editors

Although some reversible treatments for Alzheimer's disease (AD) have been suggested recently, this debilitating condition is still incurable. The majority of clinically recommended treatments today only attenuate the symptoms, enhancing AD patients' quality of life. Despite their ability to attenuate symptoms, these medicines lead to several side effects. The absence of treatments for AD is due to a number of factors, including not knowing the real mechanism of the disease, even though several mechanisms have been proposed in the literature; the drugs being limited in reaching the brain due to the existence of the blood-brain barrier; and others.

Thus far, there is an urgent need to understand the disease mechanisms better and to develop novel treatments for AD. This Special Issue aims to collect the most recent advances in new treatments proposed for disease therapy.







IMPACT FACTOR 4.9





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Department of Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers University, Piscataway, NJ 08854, USA

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Contact Us